Detection of Methylene Tetrahydrofolate Reductase Gene Polymorphism (C677T) In Sudanese Patients with Chronic Myeloid Leukemia
Chronic myeloid leukaemia (CML) is a kind of cancer that affects the white blood cells and resort to progress slowly through many years. It’s occur at any age, but is most common in older (60-65 years) of age. This is a cross sectional study aimed to detect MTHFR gene polymorphism (C677T) among Sudanese patients diagnosed with Chronic Myeloid Leukaemia and conducted at the research laboratory of the national center of neurological sciences (NCNS), Khartoum, Sudan.50 patients with Chronic Myeloid Leukemia (CML) diagnosed as BCR-ABL positive by RT-PCR used as a cases and 50 apparently healthy individuals as a control. A 5 ml of blood samples were collected in EDTA anticoagulant container for DNA Extraction and white blood cells count, hemoglobin level and platelets count. Genotyping of the MTHFR was carried out using PCR technique and the SNP (C677T) confirmed by sequencing a subset of samples. The results were analyzed using bioinformatics tools. The results showed; the most affected age group in the patients was 51-60 years followed by 41-50 years which constituted 32% and 30%, respectively. The hematological findings revealed that, the mean of TWBCs was 47.4, HB was 11.9 for patients, 7.2 and 14.1 respectively for control group (P = 0.000). PLT was 313.5 for patients and 287.5 for control group (P = 0.187). MTHFR gene was detected in the all patients (198pb) by the PCR, Sequence results were aligned with the reference sequence of MTHFR gene, the polymorphic C >T was found to be matched with the registered mutation in NCBI data base. This study provides the first evidence for associations of MTHFR gene polymorphism with the risk of chronic myeloid leukemia in Sudanese patients. The C >T genotype of the rs 677 polymorphism in MTHFR gene may have a promoting effect on chronic myeloid leukemia.
Keywords: Chronic myeloid leukaemia (CML), DNA, PCR, RT-PCR, MTHFR
2- Hehlmann R., et al. Chronic myeloid leukemia. The Lancet 2007; 370: 342-350
3- Skibola C.F., Smith M.T., Kane E., Roman E., Rollin¬son S., Cartwright R.A., Morgan G. Polymor¬phisms in the methylenetetrahydrofolate re¬ductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A 1999; 96: 12810-15
4- Cortes J. CML: Living with a chronic disease. Teleconference of The Leukemia &Lymphoma Society, Past Patient Education Programs, Leukemia. April 17, 2013.www.lls.org/#/resourcecenter/pastprograms/leukemia/041713_cml. Accessed September 10, 2014.
5- GLOBOCAN. Estimated Cancer Incidence, Mortality and Prevalence Worldwide 2012. www.globocan.iarc.fr. Accessed 21 September 2014.
6- Cortes J., Kantarjian H. How I treat newly diagnosed chronic phase CML. Blood 2012; 120(7):1390-1397.
7- Lordelo G.S., Miranda A.L., Vilela1 A.K. Akimoto P.Z., Alves C.O., Hiragi1 A., Nonino et al. reductase and glutathione S-transferase M1 gene polymorphisms and chronic myeloid leukemia in a Brazilian population. Gen and Mol Res 2012; (1): 1013-1026
8- Robien K., Ulrich C.M. 5, 10-Methylenetetrahydrofolate reductase polymorphisms and leukemia risk: a HuGE mini review. Am j Epidemiol. 2003; 157(7):571- 582.
9- Frosst P., Blom H.J., Milos R., Goyette P., Sheppard C.A., Matthews R.G., Boers G.J., den Heijer M., Kluijtmans L.A., van den Heuvel L.P. A candidate genetic risk factor for vascular disease: a com¬mon mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-13.
10- Andolina J., Neudorf S., Corey S. How I treat childhood CML. Blood. 2012; 119(8):1821-1830.
11- Ya-Zhen Qin M.S., Qian Jiang M.D., Hao Jiang M.M.S., Yue-Yun Lai M.D., Hong-Hu Zhu M.D., Yan-Rong Liu M.S,, et al . Combination of White Blood Cell Count at Presentation With Molecular Response at 3 Months Better Predicts Deep Molecular Responses to Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients. Medicine _2016; 95(2):1-9
12- Karmakar S., Banerjee D., Chakrabarti A. Platelet Proteomics in Chronic Myeloid Leukemia. Int J Blood Dis Dis. 2017; 1(1): 001-006.
13- Ueland P.M., Hustad S., Schneede J., Refsum H., Vollset S.E. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci. 2001; 22(4):195-201.
14- Botto L.D., Yang Q. 5, 10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. Am J Epidemiol. 2000; 151(9):862-877
15- Hur M., Park J.Y., Cho H.C., Lee K.M., Shin H..Y, Cho H.I. Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol. 2006; 28(3):154-159.
16- Duthie S.J., Narayanan S., Brand G.M., Pirie L., et al. Impact of folate deficiency on DNA stability. J. Nutr2002; 132: 2444S-2449S
17- Moon H.W., Kim T.Y., Oh B.R., et al. MTHFR 677CC/1298CC genotypes are highly associated with chronic myelogenous leukemia: a case-control study in Korea. Leuk Res. 2007; 31(9):1213 1217.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).